Onset and pre-onset studies to define the Huntington's disease natural history

被引:38
作者
Squitieri, F
Cannella, M
Giallonardo, P
Maglione, V
Mariotti, C
Hayden, MR
机构
[1] IRCCS Neuromed, Neurol Inst, Neurogenet Unit, I-86077 Pozzilli, IS, Italy
[2] Neurol Inst C Besta, Div Biochem & Genet, Milan, Italy
[3] Univ British Columbia, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada
关键词
predictive diagnosis; clinical history; onset symptoms;
D O I
10.1016/S0361-9230(01)00648-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease's (HD) clinical history has not been defined yet. However, many aspects of the most confusing clinical stages, i.e., the first and last disease phases, including the symptom progression and the disease duration, have been better approached after discovery of the responsible gene. The existence of accurate genetic tests, available for affected and pre-symptomatic subjects (i.e., mutation carriers) and the possibility to study transgenic in vivo models, are actually helping us to understand some of the aspects of HD clinical presentation. HD may present with motor symptoms other than chorea, the psychiatric manifestations may represent part of the clinical picture and cognitive deterioration may occur very early in the disease and depend an early cortical involvement. Pre-onset studies are of crucial importance in understanding the temporal sequence of the clinical events. This is also very important for future therapeutic strategies in those diseases initiating late in the life, such as HD. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 69 条
[1]   PREFERENTIAL LOSS OF STRIATO-EXTERNAL PALLIDAL PROJECTION NEURONS IN PRESYMPTOMATIC HUNTINGTONS-DISEASE [J].
ALBIN, RL ;
REINER, A ;
ANDERSON, KD ;
DURE, LS ;
HANDELIN, B ;
BALFOUR, R ;
WHETSELL, WO ;
PENNEY, JB ;
YOUNG, AB .
ANNALS OF NEUROLOGY, 1992, 31 (04) :425-430
[2]   THE RELATIONSHIP BETWEEN TRINUCLEOTIDE (CAG) REPEAT LENGTH AND CLINICAL-FEATURES OF HUNTINGTONS-DISEASE [J].
ANDREW, SE ;
GOLDBERG, YP ;
KREMER, B ;
TELENIUS, H ;
THEILMANN, J ;
ADAM, S ;
STARR, E ;
SQUITIERI, F ;
LIN, BY ;
KALCHMAN, MA ;
GRAHAM, RK ;
HAYDEN, MR .
NATURE GENETICS, 1993, 4 (04) :398-403
[3]  
[Anonymous], 1991, HUNTINGTONS DIS
[4]   Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease [J].
Antonini, A ;
Leenders, KL ;
Spiegel, R ;
Meier, D ;
Vontobel, P ;
WeigellWeber, M ;
SanchezPernaute, R ;
deYebenez, JG ;
Boesiger, P ;
Weindl, A ;
Maguire, RP .
BRAIN, 1996, 119 :2085-2095
[5]   Repeats may not be everything in anticipation [J].
Ashizawa, T ;
Conneally, PM .
NEUROLOGY, 1999, 53 (06) :1164-1165
[6]   REDUCED BASAL GANGLIA VOLUME ASSOCIATED WITH THE GENE FOR HUNTINGTONS-DISEASE IN ASYMPTOMATIC AT-RISK PERSONS [J].
AYLWARD, EH ;
BRANDT, J ;
CODORI, AM ;
MANGUS, RS ;
BARTA, PE ;
HARRIS, GJ .
NEUROLOGY, 1994, 44 (05) :823-828
[7]  
BENJAMIN CM, 1994, AM J HUM GENET, V55, P606
[8]  
Brinkman RR, 1997, AM J HUM GENET, V60, P1202
[9]  
BROHOLM J, 1994, NEUROLOGY, V44, P1533
[10]  
Carter RJ, 2000, MOVEMENT DISORD, V15, P925, DOI 10.1002/1531-8257(200009)15:5<925::AID-MDS1025>3.0.CO